Bicara Therapeutics (NASDAQ:BCAX) Announces Quarterly Earnings Results

Bicara Therapeutics (NASDAQ:BCAX) announced its quarterly earnings data on Tuesday. The company reported ($1.60) EPS for the quarter, missing the consensus estimate of ($0.46) by ($1.14), Zacks reports.

Bicara Therapeutics Stock Up 0.7 %

Shares of Bicara Therapeutics stock traded up $0.15 during trading hours on Wednesday, reaching $22.50. 152,879 shares of the company’s stock were exchanged, compared to its average volume of 356,837. Bicara Therapeutics has a 1 year low of $18.33 and a 1 year high of $28.09. The firm has a fifty day moving average price of $23.46.

Wall Street Analyst Weigh In

Several analysts have commented on the stock. Morgan Stanley assumed coverage on shares of Bicara Therapeutics in a research note on Tuesday, October 8th. They set an “overweight” rating and a $35.00 price objective for the company. Cantor Fitzgerald assumed coverage on shares of Bicara Therapeutics in a research note on Tuesday, October 8th. They issued an “overweight” rating for the company. Rodman & Renshaw assumed coverage on shares of Bicara Therapeutics in a research note on Tuesday, November 5th. They issued a “buy” rating and a $48.00 target price for the company. RODMAN&RENSHAW upgraded shares of Bicara Therapeutics to a “strong-buy” rating in a research note on Tuesday, November 5th. Finally, Stifel Nicolaus initiated coverage on shares of Bicara Therapeutics in a research note on Tuesday, October 8th. They issued a “buy” rating and a $47.00 target price for the company. Five analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $43.33.

Insider Buying and Selling at Bicara Therapeutics

In related news, major shareholder James E. Flynn purchased 70,000 shares of Bicara Therapeutics stock in a transaction dated Tuesday, September 17th. The shares were acquired at an average cost of $18.00 per share, with a total value of $1,260,000.00. Following the purchase, the insider now owns 897,587 shares of the company’s stock, valued at approximately $16,156,566. The trade was a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In other news, major shareholder James E. Flynn purchased 70,000 shares of the stock in a transaction on Tuesday, September 17th. The stock was bought at an average price of $18.00 per share, for a total transaction of $1,260,000.00. Following the acquisition, the insider now directly owns 897,587 shares of the company’s stock, valued at approximately $16,156,566. The trade was a 0.00 % increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Ra Capital Management, L.P. bought 1,833,000 shares of the stock in a transaction dated Monday, September 16th. The stock was bought at an average price of $18.00 per share, with a total value of $32,994,000.00. Following the acquisition, the director now owns 4,303,418 shares in the company, valued at approximately $77,461,524. This represents a 0.00 % increase in their position. The disclosure for this purchase can be found here.

Bicara Therapeutics Company Profile

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.